Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
McKesson
Medtronic
Cerilliant
AstraZeneca
US Department of Justice
US Army
McKinsey
Moodys

Generated: May 26, 2018

DrugPatentWatch Database Preview

XYZAL Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Xyzal, and what generic alternatives are available?

Xyzal is a drug marketed by Sanofi-aventis Us and is included in four NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in XYZAL is levocetirizine dihydrochloride. There are thirteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.
Drug patent expirations by year for XYZAL
Pharmacology for XYZAL
Synonyms for XYZAL
(-)-Cetirizine dihydrochloride; 2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid dihydrochloride
(2-(4-((R)-(4-Chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
(R)-Cetirizine dihydrochloride
[2-[4-[(R)-(4-Chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid 2HCl
[2-[4-[(R)-(4-CHLOROPHENYL)PHENYLMETHYL]-1-PIPERAZINYL]ETHOXY]-ACETIC ACID DIHYDROCHLORIDE
018L870
130018-87-0
2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]ethanoic acid dihydrochloride
2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
2-[2-[4-[(R)-(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid Dihydrochloride
A806003
AC-549
Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride
AK176131
AKOS015994681
API0000012
API0003160
AT-15143
BC204366
BG0136
CHEMBL1201190
CTK8F2040
D08118
FT-0631130
KS-00000XIF
KS-1177
L0264
Levoceitrizine dihydrochloride
Levocetirizine 2HCl
Levocetirizine dihydrochloride
Levocetirizine dihydrochloride (USAN)
Levocetirizine dihydrochloride [USAN]
Levocetirizine dihydrochloride, >=98% (HPLC)
Levocetirizine HCl
Levocetirizine hydrochloride (JAN)
LS-186529
MFCD07366507
MolPort-003-983-419
PGLIUCLTXOYQMV-GHVWMZMZSA-N
SCHEMBL144375
SOD6A38AGA
UCB 28556
UCB-28556
UNII-64O047KTOA component PGLIUCLTXOYQMV-GHVWMZMZSA-N
UNII-SOD6A38AGA
Xusal
Xyzal (TN)
Xyzal Allergy 24hr
Xyzall

US Patents and Regulatory Information for XYZAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride SOLUTION;ORAL 022157-001 Jan 28, 2008 AA RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi-aventis Us XYZAL ALLERGY 24HR levocetirizine dihydrochloride TABLET;ORAL 209089-001 Jan 31, 2017 OTC Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride TABLET;ORAL 022064-001 May 25, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi-aventis Us XYZAL ALLERGY 24HR levocetirizine dihydrochloride SOLUTION;ORAL 209090-001 Jan 31, 2017 OTC Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for XYZAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride TABLET;ORAL 022064-001 May 25, 2007 ➤ Sign Up ➤ Sign Up
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride SOLUTION;ORAL 022157-001 Jan 28, 2008 ➤ Sign Up ➤ Sign Up
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride TABLET;ORAL 022064-001 May 25, 2007 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for XYZAL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Oral Solution 0.5 mg/mL ➤ Subscribe 2009-01-14
➤ Subscribe Tablets 5 mg ➤ Subscribe 2007-12-17

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cerilliant
Federal Trade Commission
Accenture
Healthtrust
Chubb
US Army
Fish and Richardson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.